Anti -GROS1 (Growth Suppressor 1, Leucine- and Proline-enriched Proteoglycan 1, LEPRE1, Leprecan-1, MGC117314, OI8, Prolyl 3-hydroxylase 1, P3H1, PSEC0109)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 4; NC_000070.6 (119232915..119248977). Location: 4; 4 D1

Polyclonal

IgG

Rabbit

Recognizes human LEPRE1.

Affinity Purified
Purified by Protein A affinity chromatography.

Supplied as a liquid in PBS, pH 7.2.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-Lepre1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

GROS1 is a tumor suppressor protein encoded by a gene on human chromosome 1p31, a region mutated in many malignancies. Gros1 identity to leprecan, a basement membrane-associated proteoglycan, has been reported. The precise cellular function of GROS1 has not been determined.

Antibodies; Abs to Extracellular Matrix Proteins

Western Blot (WB)

Suitable for use in Western Blot.

83,651 Da[Similar Products]

leprecan 1

prolyl 3-hydroxylase 1; leprecan-1; growth supressor 1; growth suppressor 1; leucine- and proline-enriched proteoglycan 1

Prolyl 3-hydroxylase 1

Gros1; P3h1; Leprecan-1??[Similar Products]

P3H1_MOUSE

LEPRE1: Basement membrane-associated chondroitin sulfate proteoglycan (CSPG). Has prolyl 3-hydroxylase activity catalyzing the post-translational formation of 3-hydroxyproline in -Xaa-Pro- Gly- sequences in collagens, especially types IV and V. May be involved in the secretory pathway of cells. Has growth suppressive activity in fibroblasts. Defects in LEPRE1 are the cause of osteogenesis imperfecta type 8 (OI8). A connective tissue disorder characterized by disproportionate short stature, severe osteoporosis, shortening of the long bones, white sclerae, a round face and a short barrel-shaped chest. Belongs to the leprecan family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell development/differentiation; EC 1.14.11.7; Oxidoreductase; Secreted, signal peptide; Secreted

Cellular Component: proteinaceous extracellular matrix; membrane; endoplasmic reticulum; cytoplasm; plasma membrane; extracellular region; basement membrane; nucleus

Molecular Function: procollagen-proline 3-dioxygenase activity; L-ascorbic acid binding; dioxygenase activity; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen; metal ion binding; iron ion binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors; oxidoreductase activity

Biological Process: regulation of protein secretion; collagen fibril organization; protein folding; protein stabilization; collagen metabolic process; peptidyl-proline hydroxylation; protein amino acid hydroxylation; regulation of ossification; cell growth

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.